TY - JOUR
T1 - Update on PET glucose neuroimaging
AU - Buchsbaum, Monte S.
AU - Hazlett, Erin A.
N1 - Funding Information:
We have been supported by National Institute of Mental Health grants MH 40071 (to M.S.B.) and MH 56460 (to E.A.H.), a Young Investigator award from the National Alliance for Research on Schizophrenia and Depression (to E.A.H.), the Dana Foundation and the Seaver Foundation. The contributions of our image analysis programmers (Dr C. T. Wei and Jacqueline Spiegel-Cohen), anatomical collaborators (Drs James Fallon and Patrick Hof), statistical consultants (Drs Fred Bookstein and John Bartko), colleagues in Nuclear Medicine (Drs Joseph Machac and Karin Knesaurek) and clinical collaborators (Drs John Edgar, Mehmet Haznedar, Rami Kaminski, David Schnur and Lina Shihabuddin) have also been important.
PY - 1997
Y1 - 1997
N2 - Positron emission tomography with 18F-deoxyglucose yields high-resolution images of brain activity with accurate quantification of a fundamental property of central nervous system function, cerebral glucose metabolic rate. Alone among brain-imaging modalities, the deoxyglucose method can be applied with microscopic resolution in animal studies, permitting detailed comparison of phamacological response in both human and non-human experiments. In schizophrenia, metabolic imaging has identified functional changes in components of the fronto-striato-thalamic circuits and the temporal lobe, and visualized changes with neuroleptic, anxiolytic and antidepressant treatment.
AB - Positron emission tomography with 18F-deoxyglucose yields high-resolution images of brain activity with accurate quantification of a fundamental property of central nervous system function, cerebral glucose metabolic rate. Alone among brain-imaging modalities, the deoxyglucose method can be applied with microscopic resolution in animal studies, permitting detailed comparison of phamacological response in both human and non-human experiments. In schizophrenia, metabolic imaging has identified functional changes in components of the fronto-striato-thalamic circuits and the temporal lobe, and visualized changes with neuroleptic, anxiolytic and antidepressant treatment.
UR - http://www.scopus.com/inward/record.url?scp=0030664544&partnerID=8YFLogxK
U2 - 10.1080/09540269775213
DO - 10.1080/09540269775213
M3 - Review article
AN - SCOPUS:0030664544
SN - 0954-0261
VL - 9
SP - 339
EP - 354
JO - International Review of Psychiatry
JF - International Review of Psychiatry
IS - 4
ER -